LC
AQST icon

Lindbrook Capital’s Aquestive Therapeutics AQST Stock Holding History

Lindbrook Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-109
Closed -$543 – 2780
2024
Q3 		$543 Buy
+109
New +$424 ﹤0.01% 2646

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Lindbrook Capital's AQST Position: Q4 2024 in Review

Lindbrook Capital sold out of Aquestive Therapeutics (AQST) in Q4 2024, closing a stake of 109 shares — an estimated $543 sold.

Lindbrook Capital first reported a position in AQST in Q3 2024 and held it in 1 quarter. The position peaked at $543 in Q3 2024. 114 funds tracked by Wall St. Rank hold AQST as of Q4 2024.

  • Lindbrook Capital reported no remaining Aquestive Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 109 Aquestive Therapeutics shares in Q4 2024, an estimated $543.
  • Lindbrook Capital first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 1 quarter.
  • Lindbrook Capital's Aquestive Therapeutics position peaked at $543 in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.